scholarly journals Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study

2022 ◽  
Author(s):  
Hayato Kawachi ◽  
Motohiro Tamiya ◽  
Kinnosuke Matsumoto ◽  
Akihiro Tamiya ◽  
Takafumi Yanase ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Squamous Cell Lung Cancer ◽  
Efficacy And Safety ◽  
Previously Treated Patients ◽  
Previously Treated

scholarly journals Efficacy And Safety of Ramucirumab and Docetaxel In Previously Treated Patients With Squamous Cell Lung Cancer: A Multicenter Retrospective Cohort Study

2021 ◽  
Author(s):  
Hayato Kawachi ◽  
Motohiro Tamiya ◽  
Kinnosuke Matsumoto ◽  
Akihiro Tamiya ◽  
Takafumi Yanase ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Squamous Cell ◽  
Real World ◽  
Retrospective Cohort ◽  
Safety Data ◽  
Pulmonary Hemorrhage ◽  
Efficacy And Safety ◽  
Previously Treated Patients ◽  
Previously Treated

Abstract Objective: Ramucirumab plus docetaxel therapy (RAM/DOC) is currently the standard for previously treated advanced non-small cell lung cancer (NSCLC), irrespective of histology. However, the safety data of anti-angiogenic agents for squamous cell NSCLC (Sq) is lacking, with a higher reported rate of severe hemoptysis in a clinical trial setting. We conducted a multicenter retrospective cohort study to confirm the efficacy and safety of RAM/DOC for Sq in real-world settings.Methods: We retrospectively analyzed previously treated patients with advanced NSCLC who underwent RAM/DOC at four institutions. Clinical data on the initiation of RAM/DOC were collected from medical records. Treatment outcomes of RAM/DOC were assessed according to the Response Evaluation Criteria in Solid Tumors version 1.1. Incidence of pulmonary hemorrhage was assessed according to the Common Terminology Criteria for Adverse Events version 5.0.Results: Overall, 237 patients with NSCLC were included and 38 (16%) had squamous cell carcinoma. There were no significant differences in median progression-free survival and overall survival between Sq and non-Sq patients (5.8 months vs. 4.3 months, P=0.0937; 15.2 months vs. 13.4 months, P=0.714, respectively). Of all patients, 13 (5%) developed pulmonary hemorrhage. According to histology, there was no significant difference in pulmonary hemorrhage proportion between Sq and non-Sq cohorts (2/38 vs. 11/199, respectively, P=0.947).Conclusion: For previously treated patients with Sq, efficacy and safety data of RAM/DOC were confirmed in a real-world setting and were similar to non-Sq. Ramucirumab is the only vascular endothelial growth factor-blocker available for Sq.

scholarly journals Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology ◽  
2021 ◽  
Author(s):  
Scott N. Gettinger ◽  
Mary W. Redman ◽  
Lyudmila Bazhenova ◽  
Fred R. Hirsch ◽  
Philip C. Mack ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Stage Iv ◽  
Squamous Cell Lung Cancer ◽  
Previously Treated Patients ◽  
Previously Treated
Sign in / Sign up

Export Citation Format

Share Document